N@N

Brian Abrahams Maintained (SRPT) at Buy with Decreased Target to $151 on, Jan 25th, 2024

Brian Abrahams of RBC Capital, Maintained "Sarepta Therapeutics, Inc." (SRPT) at Buy with Decreased Target from $155 to $151 on, Jan 25th, 2024.

Brian has made no other calls on SRPT in the last 4 months.

There are 9 other peers that have a rating on SRPT. Out of the 9 peers that are also analyzing SRPT, 1 agrees with Brian's Rating of Hold. Following is the relevant analyst calls for the last 4 months

---

• Kristen Kluska of "Cantor Fitzgerald" Maintained at Hold with Increased Target to $80 on, Thursday, November 2nd, 2023

These are the ratings of the 8 analyists that currently disagree with Brian

---

• Gil Blum of "Needham" Maintained at Strong Buy with Increased Target to $140 on, Wednesday, January 10th, 2024
• Andreas Argyrides of "Wedbush" Reiterated at Buy and Held Target at $224 on, Tuesday, January 9th, 2024
• David Hoang of "Citigroup" Initiated at Strong Buy and Held Target at $113 on, Wednesday, December 13th, 2023
• Neena Bitritto-Garg of "Deutsche Bank" Initiated at Strong Buy and Held Target at $109 on, Tuesday, December 12th, 2023
• Gena Wang of "Barclays" Maintained at Buy with Decreased Target to $141 on, Thursday, November 2nd, 2023
• Anupam Rama of "JP Morgan" Maintained at Buy with Decreased Target to $115 on, Tuesday, October 31st, 2023
• Matthew Harrison of "Morgan Stanley" Maintained at Buy with Decreased Target to $146 on, Tuesday, October 31st, 2023
• Uy Ear of "Mizuho" Reiterated at Strong Buy and Held Target at $160 on, Tuesday, September 26th, 2023

Contributing Sources

---